Pretražite po imenu i prezimenu autora, mentora, urednika, prevoditelja

Napredna pretraga

Pregled bibliografske jedinice broj: 1030399

Biološka terapija i trudnoća – iskustvo tercijarnog centra


Bakula, , Marija; Kilić, , Paula; Cerovec, , Mislav; Mayer, , Miroslav; Anić, Branimir
Biološka terapija i trudnoća – iskustvo tercijarnog centra // Reumatizam, 66 (2019), 1; 10-25 doi:https//.org /10.3304/reumatizam-66-1-2 (recenziran, članak, znanstveni)


CROSBI ID: 1030399 Za ispravke kontaktirajte CROSBI podršku putem web obrasca

Naslov
Biološka terapija i trudnoća – iskustvo tercijarnog centra

Autori
Bakula, , Marija ; Kilić, , Paula ; Cerovec, , Mislav ; Mayer, , Miroslav ; Anić, Branimir

Izvornik
Reumatizam (0374-1338) 66 (2019), 1; 10-25

Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni

Ključne riječi
Reumatske bolesti – farmakoterapija ; Komplikacije u trudnoći – farmakoterapija ; Antireumatici – terapijska uporaba ; Biološki...
(Rheumatic diseases – drug therapy ; Pregnancy complications – drug therapy ; Antirheumatic agents – therapeutic use ; Biological products – therapeutic use ; Tumor necrosis factor-alpha – antagonists and inhibitors ; Antibodies, monoclonal, humanized – therapeutic use ; Pregnancy outcome)

Sažetak
Treatment of inflammatory rheumatic diseases and control of disease activity have considerably improved after the introduction of biologic therapy over a decade ago. The safety profile of biologic therapy in the preconception period as well as during pregnancy and lactation is neccessary to consider when planning the treatment of young female patients. Neither the Food and Drug Administration Agency nor the European Medicines Agency have declared biologic therapy safe during pregnancy. Both the European League Against Rheumatism and the British Society for Rheumatology proposed guidelines for the treatment of female rheumatology patients during pregnancy and lactation, and the American College of Rheumatology is currently developing guidelines for the therapeutic approach during pregnancy. On the other hand, there are numerous publications of pregnancy outcomes in patients treated with biologic therapy, with a small number of adverse effects. We analyzed the modalities of biologic therapy and pregnancy outcomes in patients treated at our Department, during planned and unplanned pregnancies. Our results do not differ from the literature published to date. Among the patients described here, 15 were treated with an inhibitor of tumor necrosis factor-α and one with an IL-6 inhibitor during or just before pregnancy. Only 2 patients stopped biologic therapy in compliance with the guidelines. Of the 16 aforementioned patients, 3 had to undergo medically-induced abortion ; one patient because of a severe fetal malformation and the other two patients because they had been treated with conventional disease-modifying antirheumatic drugs, which are contraindicated during pregnancy.

Izvorni jezik
Hrvatski, engleski

Znanstvena područja
Temeljne medicinske znanosti



POVEZANOST RADA


Profili:

Avatar Url Miroslav Mayer (autor)

Avatar Url Branimir Anić (autor)

Poveznice na cjeloviti tekst rada:

doi

Citiraj ovu publikaciju:

Bakula, , Marija; Kilić, , Paula; Cerovec, , Mislav; Mayer, , Miroslav; Anić, Branimir
Biološka terapija i trudnoća – iskustvo tercijarnog centra // Reumatizam, 66 (2019), 1; 10-25 doi:https//.org /10.3304/reumatizam-66-1-2 (recenziran, članak, znanstveni)
Bakula, , Marija, Kilić, , Paula, Cerovec, , Mislav, Mayer, , Miroslav & Anić, B. (2019) Biološka terapija i trudnoća – iskustvo tercijarnog centra. Reumatizam, 66 (1), 10-25 doi:https//.org /10.3304/reumatizam-66-1-2.
@article{article, year = {2019}, pages = {10-25}, DOI = {https//doi.org /10.3304/reumatizam-66-1-2}, keywords = {Reumatske bolesti – farmakoterapija, Komplikacije u trudno\'{c}i – farmakoterapija, Antireumatici – terapijska uporaba, Biolo\v{s}ki...}, journal = {Reumatizam}, doi = {https//doi.org /10.3304/reumatizam-66-1-2}, volume = {66}, number = {1}, issn = {0374-1338}, title = {Biolo\v{s}ka terapija i trudno\'{c}a – iskustvo tercijarnog centra}, keyword = {Reumatske bolesti – farmakoterapija, Komplikacije u trudno\'{c}i – farmakoterapija, Antireumatici – terapijska uporaba, Biolo\v{s}ki...} }
@article{article, year = {2019}, pages = {10-25}, DOI = {https//doi.org /10.3304/reumatizam-66-1-2}, keywords = {Rheumatic diseases – drug therapy, Pregnancy complications – drug therapy, Antirheumatic agents – therapeutic use, Biological products – therapeutic use, Tumor necrosis factor-alpha – antagonists and inhibitors, Antibodies, monoclonal, humanized – therapeutic use, Pregnancy outcome}, journal = {Reumatizam}, doi = {https//doi.org /10.3304/reumatizam-66-1-2}, volume = {66}, number = {1}, issn = {0374-1338}, title = {Biolo\v{s}ka terapija i trudno\'{c}a – iskustvo tercijarnog centra}, keyword = {Rheumatic diseases – drug therapy, Pregnancy complications – drug therapy, Antirheumatic agents – therapeutic use, Biological products – therapeutic use, Tumor necrosis factor-alpha – antagonists and inhibitors, Antibodies, monoclonal, humanized – therapeutic use, Pregnancy outcome} }

Časopis indeksira:


  • Scopus
  • MEDLINE


Citati:





    Contrast
    Increase Font
    Decrease Font
    Dyslexic Font